Kinase Inhibitors [MoA] class drugs

11 results

  • ibrance - palbociclib capsule

    (Palbociclib)
    Pfizer Laboratories Div Pfizer Inc
    IBRANCE treats HR-positive, HER2-negative advanced or metastatic breast cancer in adults, combined with an aromatase inhibitor or fulvestrant. It also treats PIK3CA-mutated, endocrine-resistant cases with inavolisib and fulvestrant, and HR-positive, HER2-positive metastatic breast cancer with trastuzumab and endocrine therapy for maintenance.
    Medication Details
    Savings Programs
    1
    Drug Interactions

  • ibrance - palbociclib tablet, film coated

    (Palbociclib)
    Pfizer Laboratories Div Pfizer Inc
    IBRANCE treats adults with HR-positive, HER2-negative advanced or metastatic breast cancer alongside an aromatase inhibitor or fulvestrant. It also treats endocrine-resistant, PIK3CA-mutated HER2-negative metastatic breast cancer, and HR-positive, HER2-positive metastatic breast cancer as maintenance therapy with trastuzumab and endocrine therapy.
    Medication Details
    Drug Interactions

  • pemazyre - pemigatinib tablet

    (Pemigatinib)
    Incyte Corporation
    Pemazyre treats adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or rearrangement, and adults with relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement.
    Medication Details
    Drug Interactions

  • tagrisso - osimertinib tablet, film coated

    (Osimertinib)
    Astrazeneca Pharmaceuticals Lp
    TAGRISSO treats adults with EGFR mutation-positive non-small cell lung cancer (NSCLC): as adjuvant therapy after resection, for locally advanced unresectable stage III NSCLC post-chemoradiation, as first-line treatment for metastatic NSCLC (alone or with chemotherapy), and for T790M mutation-positive NSCLC after prior EGFR TKI therapy.
    Medication Details
    Drug Interactions

  • verzenio - abemaciclib tablet

    (Abemaciclib)
    Eli Lilly And Company
    Verzenio (abemaciclib) treats HR-positive, HER2-negative breast cancer in adults. Used with endocrine therapy for high-risk early breast cancer, with an aromatase inhibitor or fulvestrant for advanced/metastatic disease, or as monotherapy after prior endocrine therapy and chemotherapy in the metastatic setting.
    Medication Details
    Drug Interactions